Canada Markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.7700+0.0900 (+3.36%)
At close: 03:59PM EDT
2.7700 0.00 (0.00%)
After hours: 05:00PM EDT

Longeveron Inc.

1951 NW 7th Avenue
Suite 520
Miami, FL 33136
United States
305 909 0840

Full Time Employees18

Key Executives

NameTitlePayExercisedYear Born
Dr. Joshua Michael Hare FACC, M.D.Co-Founder, Chief Science Officer & Chairman449.81kN/A1963
Mr. James Clavijo CPACFO & Treasurer481.07kN/A1966
Mr. Paul T. Lehr J.D.International Exec. Director, Gen. Counsel & Sec.465.25kN/A1968
Dr. Kwan-Hong Min M.D., Ph.D.Chief Medical Officer & Interim CEON/AN/A1967
Dr. Dan Gincel Ph.D.Sr. VP of Strategic Collaborations & Scientific AffairsN/AN/A1971
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Corporate Governance

Longeveron Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.